ketamine has already been approved and used as a treatment for depression, particularly treatment-resistant depression (TRD). Ketamine, traditionally known as an anesthetic and pain reliever, has gained attention in recent years for its rapid antidepressant effects, especially in individuals who have not responded well to other standard antidepressant medications.
In the United States, the U.S. Food and Drug Administration (FDA) has approved esketamine, a nasal spray formulation of ketamine, for the treatment of treatment-resistant depression in adults. Esketamine is usually administered under medical supervision in a healthcare provider's office.
It's important to note that ketamine treatment for depression is generally considered a second-line or last-resort option, used when other treatments have not been effective. It is not typically the first-line treatment for depression due to some potential side effects and concerns about its long-term use.
Since the field of medicine and research continuously evolves, there may be updates and changesdate in 2023. It is always best to consult with a healthcare professional or mental health specialist to get the most current and accurate information about ketamine as a treatment for depression in your specific region or country. They can provide you with the latest treatment options, guidelines, and any other relevant information related to ketamine's use in depression therapy.